TESC

Across TCGA pan-cancer cohorts, TESC mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TESC data layer compared with 27 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TESC mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TESC expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, UCEC, and LUAD are the cancer types where TESC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.552	0.292	.006	31	view →
UCEC	DFS	Tertile	All	0.978	0.724	.001	26	view →
LUAD	OS	Tertile	II,III,IV	0.519	0.880	.022	10	view →
LSCC	OS	Median	All	0.936	1.000	.012	8	view →
CCRCC	DFS	Median	All	0.886	0.723	.041	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TESC–PDAC (DFS)

Open the PDAC breakdown →